
The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing zzso a novel zzso zzso zzso for the prevention of zzso zzso and vomiting during the first cycle in patients receiving moderately zzso chemotherapy zzso 

zzso female patients zzso diagnosed with breast cancer zzso who were zzso and scheduled to receive an zzso and zzso zzso zzso regimen were enrolled onto this zzso randomized, zzso zzso zzso clinical zzso All patients received zzso 8 zzso zzso zzso on day 1 and oral zzso 8 zzso twice daily on days 1 to zzso Patients were randomly assigned to a control arm zzso a single oral dose zzso arm zzso zzso orally zzso on day 1), a zzso oral zzso arm zzso zzso PO on day 1 plus 50 zzso PO on days 2 to zzso or a zzso zzso zzso arm (90 zzso IV on day 1 plus 50 zzso PO on days 2 to zzso The primary end point was the proportion of patients achieving complete response (no zzso or rescue zzso in the first 120 hours after the initiation of zzso 

A significantly greater proportion of patients in the zzso oral zzso arm, zzso oral zzso arm, and zzso zzso zzso arm achieved complete response zzso zzso and zzso zzso versus control zzso P zzso zzso The study did not demonstrate a reduced proportion of patients with zzso or significant zzso in those receiving zzso zzso events were balanced among study zzso 

All zzso regimens studied were more effective than the control zzso zzso was generally well zzso 

